![](data:image/svg+xml;base64,PD94bWwgdmVyc2lvbj0iMS4wIiBlbmNvZGluZz0iVVRGLTgiPz4KPHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHhtbG5zOnhsaW5rPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5L3hsaW5rIiB3aWR0aD0iMTQ4Ny41cHQiIGhlaWdodD0iMTkyNXB0IiB2aWV3Qm94PSIwIDAgMTQ4Ny41IDE5MjUiIHZlcnNpb249IjEuMiI+CjxnIGlkPSJzdXJmYWNlNSI+CjwvZz4KPC9zdmc+Cg==)
"Wholesale distributor of prescription drugs." As defined
under section 3 of the act of December 14, 1992 (P.L.1116,
No.145), known as the Wholesale Prescription Drug Distributors
License Act.
Section 3. Study on wholesale importation of prescription
drugs.
(a) General rule.--The department shall conduct a study and
issue a report regarding the wholesale importation of
prescription drugs from Canada into this Commonwealth.
(b) Report.--At a minimum, the report shall:
(1) Identify prescription drugs with the highest
potential for consumer savings if imported through a program.
(2) Estimate savings to consumers and the Commonwealth
if a program were to be established.
(3) Evaluate the likelihood of participation in a
program by consumers, pharmacies, health care providers,
health insurance companies and other relevant stakeholders.
(4) Identify the extent to which prescription drugs
imported through a program could comply with the tracking and
tracing requirements of 21 U.S.C. §§ 360eee (relating to
definitions) and 360eee-1 (relating to agreements) prior to
the importation of the drugs into this Commonwealth.
(5) Estimate the costs of operating a program.
(6) Identify a method of financial support for a
program, including, but not limited to, a charge or fee per
prescription drug.
(7) Assess, in consultation with the Office of Attorney
General, the potential for anticompetitive behavior.
(8) Provide legislative recommendations regarding the
establishment of a program.
20200HB2225PN3166 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30